Smith & Nephew Plc share price today
(NASDAQ: SNN)

Name: Smith & Nephew Plc Share Price Today (NASDAQ: SNN) - Smith & Nephew Plc Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Smith & Nephew Plc share price is $24.99 & ₹2,161.39 as on 24 Jan 2025, 2.30 'hrs' IST

$24.99

▲

-0.24

(-0.95%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Smith & Nephew Plc share price in Dollar and Rupees. Guide to invest in Smith & Nephew Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Smith & Nephew Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Smith & Nephew Plc share price movements

Today's Low: $24.85
Today's High: $25.14
$24.99
0.56%
Downside
Day's Volatility :1.15%
Upside
0.6%
52 Weeks Low: $23.65
52 Weeks High: $31.72
$24.99
5.36%
Downside
52 Weeks Volatility :25.44%
Upside
21.22%

Smith & Nephew Plc Returns

Period	Smith & Nephew Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-11.07%	-5.5%	0.0%
6 Months	-12.79%	-4.3%	0.0%
1 Year	-9.63%	1.6%	0.0%
3 Years	-24.26%	9.8%	-11.0%

Smith & Nephew Plc Key Statistics

in dollars & INR

Previous Close	$25.23
Open	$25.12
Today's High	$25.14
Today's Low	$24.85
Market Capitalization	$11.2B
Today's Volume	$625.9K
52 Week High	$31.72
52 Week Low	$23.65
Revenue TTM	$5.6B
EBITDA	$1.1B
Earnings Per Share (EPS)	$0.7
PE Ratio	36.74
Dividend Yield	2.92%
Profit Margin	5.41%
Quarterly Earnings Growth YOY	0.24%
Return On Equity TTM	5.84%

How to invest in Smith & Nephew Plc Stock (SNN) from India?

It is very easy for Indian residents to invest directly in Smith & Nephew Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Smith & Nephew Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Smith & Nephew Plc or SNN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Smith & Nephew Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Smith & Nephew Plc shares which would translate to 0.035 fractional shares of Smith & Nephew Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Smith & Nephew Plc, in just a few clicks!

Returns in Smith & Nephew Plc for Indian investors in Rupees

Investment Value

₹1,00,000

Smith & Nephew Plc investment value today

Current value as on today

₹93,560

Returns

₹6,440

(-6.44%)

Returns from Smith & Nephew Plc Stock

₹10,494 (-10.49%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Smith & Nephew Plc

38%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Smith & Nephew Plc on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 38% more investors are searching Smith & Nephew Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Smith & Nephew Plc

Fiduciary Management, Inc. of Milwaukee
0.97%
Barrow Hanley Mewhinney & Strauss LLC
0.91%
Scharf Investments
0.67%
Goldman Sachs Group Inc
0.56%
TPG GP A, LLC
0.34%
Morgan Stanley - Brokerage Accounts
0.30%

Analyst Recommendation on Smith & Nephew Plc

Buy

70%Buy

25%Hold

4%Sell

Based on 24 Wall street analysts offering stock ratings for Smith & Nephew Plc(by analysts ranked 0 to 5 stars)

Based on 24 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Smith & Nephew Plc

What analysts predicted

Upside of 30.27%

Target:

$32.55

Current:

$24.99

Insights on Smith & Nephew Plc

Price Movement
In the last 3 months, SNN stock has moved down by -13.7%
Increasing Revenue
Revenue is up for the last 3 quarters, 1.40B → 1.41B (in $), with an average increase of 0.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 45.5M → 107.0M (in $), with an average increase of 28.7% per quarter
SNN vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 65.5% return, outperforming this stock by 76.0%
SNN vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 133.4% return, outperforming this stock by 159.0%
Price to Sales
ForSNN every $1 of sales, investors are willing to pay $9.7, whereas for Boston Scientific Corp., the investors are paying $9.3 for every $1 of sales.

Smith & Nephew Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$4.9B	↑ 2.92%
Net Income	$663.0M	↓ 13.56%
Net Profit Margin	13.52%	↓ 2.58%

	FY19	Y/Y Change
Revenue	$5.1B	↑ 4.77%
Net Income	$600.0M	↓ 9.5%
Net Profit Margin	11.68%	↓ 1.84%

	FY20	Y/Y Change
Revenue	$4.6B	↓ 11.25%
Net Income	$448.0M	↓ 25.33%
Net Profit Margin	9.82%	↓ 1.86%

	FY21	Y/Y Change
Revenue	$5.2B	↑ 14.3%
Net Income	$524.0M	↑ 16.96%
Net Profit Margin	10.05%	↑ 0.23%

	FY22	Y/Y Change
Revenue	$5.2B	↑ 0.06%
Net Income	$223.0M	↓ 57.44%
Net Profit Margin	4.28%	↓ 5.77%

	FY23	Y/Y Change
Revenue	$5.5B	↑ 6.4%
Net Income	$263.0M	↑ 17.94%
Net Profit Margin	4.74%	↑ 0.46%

	Q1 FY23	Q/Q Change
Revenue	$1.4B	↓ 50.16%
Net Income	$86.0M	↑ 78.23%
Net Profit Margin	6.29%	↑ 4.53%

	Q2 FY23	Q/Q Change
Revenue	$2.7B	↑ 100.0%
Net Income	$172.0M	↑ 100.0%
Net Profit Margin	6.29%	↑ 0.0%

	Q3 FY23	Q/Q Change
Revenue	$1.4B	↓ 48.52%
Net Income	$45.5M	↓ 73.55%
Net Profit Margin	3.23%	↓ 3.06%

	Q4 FY23	Q/Q Change
Revenue	$1.4B	↑ 0.0%
Net Income	$45.5M	↑ 0.0%
Net Profit Margin	3.23%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$1.4B	↑ 0.43%
Net Income	$107.0M	↑ 135.16%
Net Profit Margin	7.57%	↑ 4.34%

	Q2 FY24	Q/Q Change
Revenue	$1.4B	↑ 0.0%
Net Income	$107.0M	↑ 0.0%
Net Profit Margin	7.57%	↑ 0.0%

	FY18	Y/Y Change
Profit	$3.6B	↑ 2.53%

	FY19	Y/Y Change
Profit	$3.8B	↑ 5.57%

	FY20	Y/Y Change
Profit	$3.2B	↓ 16.89%

	FY21	Y/Y Change
Profit	$3.7B	↑ 15.96%

	FY22	Y/Y Change
Profit	$3.7B	↑ 0.16%

	FY23	Y/Y Change
Profit	$3.8B	↑ 3.92%

	Q1 FY23	Q/Q Change
Profit	$949.0M	↓ 51.04%

	Q2 FY23	Q/Q Change
Profit	$1.9B	↑ 100.0%

	Q3 FY23	Q/Q Change
Profit	$997.0M	↓ 47.47%

	Q4 FY23	Q/Q Change
Profit	$997.0M	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$987.0M	↓ 1.0%

	Q2 FY24	Q/Q Change
Profit	$987.0M	↑ 0.0%

	FY18	Y/Y Change
Operating Cash Flow	$931.0M	↓ 14.59%
Investing Cash Flow	$-378.0M	↓ 30.39%
Financing Cash Flow	$-371.0M	↓ 14.52%

	FY19	Y/Y Change
Operating Cash Flow	$1.2B	↑ 25.46%
Investing Cash Flow	$-1.3B	↑ 230.95%
Financing Cash Flow	$7.0M	↓ 101.89%

	FY20	Y/Y Change
Operating Cash Flow	$935.0M	↓ 19.95%
Investing Cash Flow	$-606.0M	↓ 51.56%
Financing Cash Flow	$1.2B	↑ 16528.57%

	FY21	Y/Y Change
Operating Cash Flow	$877.0M	↓ 6.2%
Investing Cash Flow	$-691.0M	↑ 14.03%
Financing Cash Flow	$-645.0M	↓ 155.41%

	FY22	Y/Y Change
Operating Cash Flow	$468.0M	↓ 46.64%
Investing Cash Flow	$-472.0M	↓ 31.69%
Financing Cash Flow	$-926.0M	↑ 43.57%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$56.5M	↓ 56.7%
Investing Cash Flow	$-91.0M	↓ 80.72%
Financing Cash Flow	$-43.0M	↓ 61.26%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$56.5M	↑ 0.0%
Investing Cash Flow	$-182.0M	↑ 100.0%
Financing Cash Flow	$-43.0M	↑ 0.0%

Smith & Nephew Plc Technicals Summary

Sell

Neutral

Buy

Smith & Nephew Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Smith & Nephew Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Smith & Nephew Plc	3.23%	-12.79%	-9.63%	-24.26%	-48.98%
Medtronic Plc	7.73%	11.61%	2.39%	-15.68%	-26.33%
Edwards Lifesciences Corp.	-8.41%	10.69%	-6.13%	-36.94%	-9.52%
Boston Scientific Corp.	10.15%	33.89%	64.9%	135.97%	135.19%
Stryker Corporation	5.32%	17.73%	25.19%	56.65%	81.96%
Abbott Laboratories	2.63%	11.92%	4.74%	-4.45%	31.47%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Smith & Nephew Plc	36.74	36.74	0.42	1.32	0.06	0.05	0.03	5.96
Medtronic Plc	27.03	27.03	1.5	5.46	0.08	0.04	0.03	38.29
Edwards Lifesciences Corp.	26.66	26.66	6.43	2.55	0.19	0.11	NA	16.18
Boston Scientific Corp.	83.4	83.4	1.79	2.46	0.09	0.05	NA	14.05
Stryker Corporation	42.47	42.47	2.68	12.06	0.19	0.07	0.01	52.86
Abbott Laboratories	34.45	34.45	2.2	4.67	0.15	0.06	0.02	22.94

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Smith & Nephew Plc	Buy	$11.2B	-48.98%	36.74	5.41%
Medtronic Plc	Buy	$113.3B	-26.33%	27.03	12.06%
Edwards Lifesciences Corp.	Buy	$40.7B	-9.52%	26.66	65.86%
Boston Scientific Corp.	Buy	$148.7B	135.19%	83.4	11.26%
Stryker Corporation	Buy	$150.9B	81.96%	42.47	16.34%
Abbott Laboratories	Buy	$202.6B	31.47%	34.45	13.99%

Smith & Nephew Plc Dividend announcements

Smith & Nephew Plc Dividends December, 2024
In the quarter ending December,2024. Smith & Nephew Plc has declared dividend of $0.29
Read More

About Smith & Nephew Plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Organization	Smith & Nephew Plc
Employees	18000
CEO	Dr. Deepak S. Nath Ph.D.
Industry	Health Technology

Management People of Smith & Nephew Plc

Name	Title
Dr. Deepak S. Nath Ph.D.	CEO & Director
Mr. John Terence Rogers	CFO & Executive Director
Mr. Andrew Swift	Vice President of Investor Relations
Mr. Joe Metzger	Senior Vice President of Marketing Services & Communications
Mr. Philip G. Cowdy	Chief Corporate Development & Corporate Affairs Officer
Ms. Elga Lohler	Chief Human Resources Officer
Dr. Vasant Padmanabhan Ph.D.	President of Research & Development and Ear, Nose & Throat
Steve Kane	Head of Human Resources for the US, Global Marketing and Global R&D
Mr. Ian Clifford Melling F.C.A.	Senior Vice President of Group Finance
Mr. Scott Schaffner	President of Sports Medicine

Important FAQs about investing in Smith & Nephew Plc (SNN) from India :

What is Smith & Nephew Plc share price today?

Smith & Nephew Plc share price today stands at $24.99, Open: $25.12 ; Previous Close: $25.23 ; High: $25.14 ; Low: $24.85 ; 52 Week High: $31.72 ; 52 Week Low: $23.65. The stock opens at $25.12, after a previous close of $25.23. The stock reached a daily high of $25.14 and a low of $24.85, with a 52-week high of $31.72 and a 52-week low of $23.65.

Can Indians buy Smith & Nephew Plc shares?

Yes, Indians can invest in the Smith & Nephew Plc (SNN) from India.

With INDmoney, you can buy Smith & Nephew Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Smith & Nephew Plc at zero transaction cost.

How can I buy Smith & Nephew Plc shares from India?

It is very easy to buy Smith & Nephew Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Smith & Nephew Plc be purchased?

Yes, you can buy fractional shares of Smith & Nephew Plc with INDmoney app.

What are the documents required to start investing in Smith & Nephew Plc stocks?

To start investing in Smith & Nephew Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.